2026 Global: Clinical Diagnostics Market-Competitive Review (2032) report
Description
The 2026 Global: Clinical Diagnostics Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for clinical diagnostics market by geography and historical trend. The scope of the report extends to sizing of the clinical diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The clinical diagnostics market is dominated by ten major companies: Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, GE Healthcare, Danaher, Philips Healthcare, Becton Dickinson (BD), Quest Diagnostics, Labcorp, and Ortho Clinical Diagnostics. These firms lead through innovations in imaging, molecular testing, point-of-care devices, and laboratory services, generating billions in revenue amid rising demand for precision medicine and AI-driven tools. Roche Diagnostics, headquartered in Switzerland with U.S. operations in Indianapolis, reported $17.7 billion in diagnostics revenue in 2024, bolstered by CE Mark approvals for glucose monitoring and WHO prequalifications for cervical cancer screening, plus the 2023 acquisition of LumiraDx’s point-of-care technology. Abbott Laboratories, based in Chicago, achieved $28.34 billion in medical devices and diagnostics in 2024, excelling in real-time molecular tools that enable faster clinical decisions. Siemens Healthineers, with $25.69 billion revenue, advances precision diagnostics via AI solutions for imaging and cancer care.
Danaher Corporation, an American conglomerate, oversees diagnostics subsidiaries like Beckman Coulter and Leica Biosystems, contributing to its $9.8 billion segment amid biotechnology expansions. GE Healthcare, spun off in 2023, posted $19.67 billion in 2024 from medical imaging, ultrasound, and PET radiotracers, including FDA approvals and the Nihon Medi-Physics acquisition. Philips Healthcare, a Dutch leader, grew diagnosis revenues within its €18.2 billion 2023 total, focusing on connected care despite challenges. Becton Dickinson (BD), founded in 1906, delivers $21.7 billion via integrated diagnostics, reagents, and automation for biosciences. Quest Diagnostics, New Jersey-based, offers broad services like clinical trials and drug screening, though revenues dipped to $9.252 billion in 2023 post-COVID testing decline.
Labcorp Holdings conducts over 600 million tests yearly, with $13 billion revenue, maintaining strong U.S. presence near the Research Triangle. Ortho Clinical Diagnostics impacts 800,000 patients daily through in vitro diagnostics for hospitals and labs worldwide. These companies drive market growth via automation, real-time analytics, and global expansions, navigating post-pandemic shifts while prioritizing infectious disease, oncology, and cardiology solutions.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for clinical diagnostics market by geography and historical trend. The scope of the report extends to sizing of the clinical diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The clinical diagnostics market is dominated by ten major companies: Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, GE Healthcare, Danaher, Philips Healthcare, Becton Dickinson (BD), Quest Diagnostics, Labcorp, and Ortho Clinical Diagnostics. These firms lead through innovations in imaging, molecular testing, point-of-care devices, and laboratory services, generating billions in revenue amid rising demand for precision medicine and AI-driven tools. Roche Diagnostics, headquartered in Switzerland with U.S. operations in Indianapolis, reported $17.7 billion in diagnostics revenue in 2024, bolstered by CE Mark approvals for glucose monitoring and WHO prequalifications for cervical cancer screening, plus the 2023 acquisition of LumiraDx’s point-of-care technology. Abbott Laboratories, based in Chicago, achieved $28.34 billion in medical devices and diagnostics in 2024, excelling in real-time molecular tools that enable faster clinical decisions. Siemens Healthineers, with $25.69 billion revenue, advances precision diagnostics via AI solutions for imaging and cancer care.
Danaher Corporation, an American conglomerate, oversees diagnostics subsidiaries like Beckman Coulter and Leica Biosystems, contributing to its $9.8 billion segment amid biotechnology expansions. GE Healthcare, spun off in 2023, posted $19.67 billion in 2024 from medical imaging, ultrasound, and PET radiotracers, including FDA approvals and the Nihon Medi-Physics acquisition. Philips Healthcare, a Dutch leader, grew diagnosis revenues within its €18.2 billion 2023 total, focusing on connected care despite challenges. Becton Dickinson (BD), founded in 1906, delivers $21.7 billion via integrated diagnostics, reagents, and automation for biosciences. Quest Diagnostics, New Jersey-based, offers broad services like clinical trials and drug screening, though revenues dipped to $9.252 billion in 2023 post-COVID testing decline.
Labcorp Holdings conducts over 600 million tests yearly, with $13 billion revenue, maintaining strong U.S. presence near the Research Triangle. Ortho Clinical Diagnostics impacts 800,000 patients daily through in vitro diagnostics for hospitals and labs worldwide. These companies drive market growth via automation, real-time analytics, and global expansions, navigating post-pandemic shifts while prioritizing infectious disease, oncology, and cardiology solutions.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.